Celldex Therapeutics Files Definitive Proxy Statement
Ticker: CLDX · Form: DEF 14A · Filed: Apr 21, 2025 · CIK: 744218
| Field | Detail |
|---|---|
| Company | Celldex Therapeutics, Inc. (CLDX) |
| Form Type | DEF 14A |
| Filed Date | Apr 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
Related Tickers: CLDX
TL;DR
Celldex proxy out - vote on board, auditors, exec pay for 2024.
AI Summary
Celldex Therapeutics, Inc. filed its definitive proxy statement on April 21, 2025, for its annual meeting on June 5, 2025. The filing details executive compensation, board nominations, and other corporate governance matters for the fiscal year ending December 31, 2024. Shareholders will vote on proposals including the election of directors and the ratification of the independent registered public accounting firm.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on company leadership and governance, impacting the strategic direction and financial oversight of Celldex Therapeutics.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) that provides information to shareholders and does not contain new material events or financial disclosures.
Key Numbers
- 2024 — Fiscal Year End (Information pertains to the fiscal year ending December 31, 2024.)
Key Players & Entities
- Celldex Therapeutics, Inc. (company) — Registrant
- 0001104659-25-036562 (filing_id) — Accession Number
- 20250421 (date) — Filing Date
- 20250605 (date) — Meeting Date
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with information regarding the company's annual meeting, including proposals to be voted on, such as the election of directors and ratification of auditors.
When is the annual meeting of Celldex Therapeutics, Inc. shareholders?
The annual meeting of Celldex Therapeutics, Inc. shareholders is scheduled for June 5, 2025.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on April 21, 2025.
What are some of the key items shareholders will vote on?
Shareholders will vote on proposals including the election of directors and the ratification of the independent registered public accounting firm.
What is the company's fiscal year end?
Celldex Therapeutics, Inc.'s fiscal year ends on December 31.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 21, 2025 regarding Celldex Therapeutics, Inc. (CLDX).